Work

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.5513

Authors: Andrea Varga, Sarina Anne Piha-Paul, Patrick Alexander Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Anne Morosky, Guo Qing Zhao, Reshma A. Rangwala, Daniela Matei

Institutions: Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Rutgers Cancer Institute, Institut de Cancérologie de l'Ouest, Merck & Co., Inc., Rahway, NJ, USA (United States), Northwestern University

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2766806972

Cites:

Cited by: 49

Related to: 10